Workshops
Friday 14 February | 7:00am - 8:00am | Breakfast included
Reveal the power of the 6-base genome: how multiomic 6-base data from cell-free DNA enhances the performance of liquid biopsy classifiers and early cancer detection
Liquid biopsy (LBX) for profiling cell-free DNA (cfDNA) in blood is a promising method to enhance cancer management through early detection, monitoring and identification of residual disease. Early research focused on detecting actionable somatic mutations, but recent advancements have incorporated methylation. 5-methylcytosine (5mC) profiles of cancer are differential to non-cancer, and recent research has suggested that 5-hydroxymethylcytosine (5hmC) profiles in cfDNA can be a marker for early cancer.
We present a technology that sequences whole genome 6-base data (A, C, G, T, 5mC, and 5hmC) at single base resolution from cfDNA extracted from healthy volunteers and patients with colorectal cancer at stages I-IV. Our findings indicate that separate measurements of 5mC and 5hmC significantly enhance diagnostic accuracy for the detection of stage I CRC (AUC = 0.95) compared to traditional approaches that conflate these markers (modified C, AUC = 0.66). Notably, most regions with an increase in 5hmC in stage I CRC cfDNA also decreased in 5mC in stage IV CRC, suggesting that 5hmC can effectively track regions undergoing demethylation during tumour development. These results support the hypothesis that distinguishing between 5mC and 5hmC can improve the sensitivity of liquid biopsy tests for early cancer detection.
SPEAKER:
Donna McDade Walker, Vice President, Global Marketing and Product Management
Proudly brought to you by:
Friday 14 February | 1:15pm - 2:15pm | Lunch included
In Vivo mRNA CARs
Advancing the Frontier of In Vivo mRNA CAR Therapy
1. Setting the stage for the discussion on the progress and future potential of in vivo mRNA CAR therapies.
2. A comprehensive review of the latest clinical data on mRNA CAR therapies, including safety, efficacy, and patient outcomes.
Key Focus: Highlights of initial clinical findings and their implications for the future of in vivo applications.
3. Detailed analysis of correlative data, exploring biomarkers, immune responses, and molecular profiles associated with mRNA CAR activity.
Key Focus: Linking correlative data to clinical outcomes and optimising therapeutic potential.
4. Introduction to innovative receptor designs and their role in expanding the applicability of mRNA CAR therapies.
Key Focus: Engineering receptors to improve specificity, durability, and therapeutic versatility.
SPEAKERS:
Daniel Getts, Founder & Chief Financial Officer – Myeloid Therapeutics
Matthew Maurer, Chief Medical Officer – Myeloid Therapeutics
Robert Hofmeister, Chief Scientific Officer – Myeloid Therapeutics
Phil Darcy, NHMRC L3 Investigator Fellow and Laboratory Head Cancer Immunotherapy - Peter MacCallum Cancer Centre
Alex Swarbreck, Principal Research Fellow & Co-Lead of the Cancer Ecosystems Program - Garvan Institute of Medical Research
Proudly brought to you by:
Saturday 15 February | 1:15pm - 2:15pm | Lunch included
CRISPR Screens, TCR/BCR Sequencing and other approaches for Cancer Drug Target and Biomarker Discovery
Overview of Cellecta technologies including CRISPR / RNAi screening and T-cell receptor (TCR) and B-cell receptor (BCR) repertoire profiling. We will highlight:
Applications for drug target and biomarker discovery and validation, summarizing key publications
Utility for obtaining insights into drug mechanisms of action and drug resistance
SPEAKERS:
Alex Chenchik, PhD, President & Chief Scientist - Cellecta
Paul Diehl, PhD, Chief Operating Officer - Cellecta
Proudly brought to you by:
